Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
Hepatitis A
Japanese encephalitis
Meningococcal disease
SAGE documentation
GRADE table
Clear all
Type of publications
SAGE documentation
(19)
Topics
GRADE table
(19)
Available to download in languages
English (EN)
(19)
Regions
Countries
Diseases
Hepatitis A
(6)
Japanese encephalitis
(9)
Meningococcal disease
(4)
Cholera
(1)
COVID-19
(2)
Dengue
(6)
Diphtheria
(1)
Haemophilus influenzae type B
(3)
Human papillomavirus (HPV)
(9)
Influenza
(11)
Measles
(6)
Pertussis
(2)
Rubella
(1)
Typhoid
(2)
Vaccine topics
Target population
Newborn
(3)
Publication date
2022
(1)
2015
(13)
2012
(5)
19 results found
2022
∙
SAGE
Annexes to the 2022 WHO Hepatitis A Vaccine Position Paper
2015
∙
SAGE
Duration of protection conferred by MenA conjugate vaccination in immunocompetent children (3 to 24 months of age) against serogroup A meningococcal disease
2015
∙
SAGE
Efficacy of a single-dose MenA conjugate vaccination in immunocompetent children (9 to 24 months of age) against serogroup A meningococcal disease
2015
∙
SAGE
Efficacy of a two dose schedule of MenA conjugate vaccination in immunocompetent children (3 to 9 months of age) against serogroup A meningococcal disease
2015
∙
SAGE
Safety of MenA conjugate vaccination in immunocompetent children (3 to 24 months of age)
2015
∙
SAGE
What is the risk of serious adverse events following vaccination with live attenuated JE vaccine?
2015
∙
SAGE
What is the risk of serious adverse events following vaccination with live recombinant JE vaccine?
2015
∙
SAGE
Is there a need for a booster dose following immunization with one dose of live attenuated JE vaccine in individuals living in JE-endemic areas?
2015
∙
SAGE
Is there a need for a booster dose following immunization with a single dose of live recombinant JE vaccine in vaccinees living in JE-endemic areas?
2015
∙
SAGE
Is there a need for a booster dose following immunization with the primary series of inactivated Vero cell-derived JE vaccine in individuals living in JE-endemic areas?
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register